top of page

2022-Alzheimer's Association International Conference

Title: Targeting the Correct Population for Trials: A Post-hoc Analysis of Trial of Solanezumab for Mild Dementia Due to Alzheimer’s disease.

Authors: Ali Ezzati, MD; Kellen K. Petersen, PhD, Bhargav Nallapu, PhD, Christian Habeck, PhD; Charles Hall, PhD; Christos Davatzikos, PhD; David Wolk, PhD; & Richard B. Lipton, MD

Download PDF • 456KB

Disclaimer: Neurodiction LLC, has no relationship with this work. The post is for informational purposes only.

77 views0 comments

Recent Posts

See All

Title: "Assessing Risk of Incident Cognitive Impairment Using Stages of Objective Memory Impairment (SOMI) and CSF biomarkers" Authors: Kellen K. Petersen PhD, Ellen Grober PhD, Richard B. Lipton MD,

Title: Comparison of Plasma-based Biomarkers and Cognitive Assessments in predicting progression of MCI to Dementia Authors: Bhargav T. Nallapu, PhD, Kellen K. Petersen, PhD, Richard B. Lipton, MD, Da

Title: Stages of Objective Memory Impairment (SOMI) Predicts Incident Cognitive Impairment: Results from the Knight ADRC Authors: Ellen Grober PhD, Kellen K. Petersen PhD, Ali Ezzati MD, Jason Hassen

Post: Blog2_Post
bottom of page